Nebraska Man Undergoes Groundbreaking Gene Therapy for Sickle Cell Anemia in St. Louis
A 20-year-old man from Nebraska traveled to St. Louis in 2025 to undergo a gene therapy called Lyfgenia for sickle cell anemia. The treatment, approved by the FDA in late 2023, showed significant results, with the patient reporting his body…
St. Louis, MO, August 10, 2026 —
A 20-year-old man from Nebraska traveled to St. Louis in 2025 to receive a novel gene therapy for sickle cell anemia. The treatment, known as Lyfgenia, was approved by the U.S. Food and Drug Administration (FDA) in late 2023.
Following the procedure, the patient reported that his body was nearly free of sickle cells, marking a significant improvement after two decades of living with the chronic condition. Sickle cell anemia is a genetic disorder that affects red blood cells, causing them to form a rigid, sickle shape. These sickle cells can impede blood flow, leading to pain, organ damage, and other serious health issues.
The Lyfgenia therapy utilizes the patient’s own stem cells. These cells are collected, genetically modified outside the body to correct the underlying defect, and then reintroduced into the patient. Prior to the reinfusion of the modified stem cells, patients undergo high-dose chemotherapy to prepare their body for the new cells.
The timeline for the patient’s treatment began with his travel to St. Louis in 2025. While specific details regarding the duration of the treatment process or any immediate post-treatment monitoring were not provided, the initial outcome reported by the patient indicates a positive response to the gene therapy.
The FDA’s approval of Lyfgenia in late 2023 represented a significant advancement in the treatment landscape for sickle cell anemia, offering a potential one-time curative option for eligible patients.
Story summarized from the original created by LeAnne Gendreau on www.firstalert4.com, see more information here.
